Table. Study and Patient Characteristics.
| Characteristic | Median (IQR) |
|---|---|
| Study characteristics | |
| Cohort size, No. (%) | |
| <100 | 5 (38) |
| ≥100 | 8 (62) |
| Design, No. (%) | |
| Prospective | 3 (23) |
| Retrospective | 10 (77) |
| Single center | 10 (77) |
| Multicenter | 3 (23) |
| Origin, No. (%) | |
| US | 11 (85) |
| Europe | 1 (8) |
| Asia | 1 (8) |
| Duration of follow-up, d | 487 (294-530) |
| Patient characteristics | |
| Age, y | 61.0 (58.7-63.0) |
| Sex, No. (%) | |
| Male | 1016 (66) |
| Female | 512 (34) |
| BMI | 27.3 (27.0-28.4) |
| Diabetes, % | 12.5 (9.8-17.0) |
| Hypertension, % | 37.5 (34.7-43.0) |
| Hypercholesterolemia, % | 32.0 (22.8-38.5) |
| Smoking history, % | 35.0 (21.9-40.4) |
| Atrial fibrillation, % | 12.0 (8.4-13.0) |
| Heart failure, % | 5.5 (3.7-7.8) |
| Coronary artery disease, % | 8.9 (7.1-10.2) |
| LVEF, % | 59.8 (58.3-61.0) |
| Underlying malignant neoplasm, % | |
| Leukemia | 7.9 (0.8-20.8) |
| Lymphoma | 80.0 (30.0-98.0) |
| Myeloma | 0.0 (0.0-8.5) |
| CAR T-cell product, % | |
| Axicabtagene ciloleucel (Yescarta) | 50.0 (39.0-61.1) |
| Tisagenlecleucel (Kymriah) | 12.0 (6.0-16.8) |
| Brexucabtagene autoleucel (Tecartus) | 0.0 (0.0-4.0) |
| Previous anthracycline therapy, % | 85.0 (80.0-87.1) |
| Previous radiotherapy, % | 17.5 (10.5-26.8) |
| Previous stem cell transplant, % | 27.0 (24.3-40.0) |
| CRS, % | |
| Overall | 75.0 (60.0-81.7) |
| Grade ≥2a | 31.0 (17.0-54.0) |
| Tocilizumab use | 49.6 (41.4-55.4) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CAR, chimeric antigen receptor; CRS, cytokine release syndrome; LVEF, left ventricular ejection fraction.
a
Grades 1 to 4, with higher grades indicating increased severity.